Influenza Vaccine Market size is set to grow by USD 2.93 billion from 2023-2027, increasing prevalence and incidence of influenza boost the market, Technavio [Yahoo! Finance]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Yahoo! Finance
The market is estimated to grow at a CAGR of 6.89% during the forecast period. The global influenza vaccine market is experiencing growth due to rising influenza cases and hospitalizations, particularly in the US. According to CDC data, 39-56 million people had flu from Oct 2019 to Mar 2020 , leading to 400,000-730,000 hospitalizations. Severe cases, children, and regional epidemics are driving demand for influenza vaccines, including combination, mRNA, swine flu, and inactivated types. Vaccines are available at hospitals & pharmacies, and include quadrivalent, adult, and pediatric options. Influenza viruses continually evolve, requiring updated vaccine strains for seasonal influenza vaccines. For more insights on the historic (2017 - 2021) and forecast market size Request a sample report Influenza Vaccine Market Scope Report Coverage Details Base year Historic period Forecast period Growth momentum & CAGR Accelerate at a CAGR of 6.89% Market growth 2023-2027 USD
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune, Inc. (NASDAQ: ALT) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.MarketBeat
- Altimmune Statement on the Passing of Dr. Stephen HarrisonGlobeNewswire
- Global COVID-19 Testing Strategic Analysis Report 2024: Market to Reach $5.8 Billion by 2030 from $19.9 Billion in 2023 [Yahoo! Finance]Yahoo! Finance
- Buy Altimmune's Potential Market Disruption With Pemvidutide [Seeking Alpha]Seeking Alpha
- Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
ALT
Earnings
- 3/27/24 - Miss
ALT
Sec Filings
- 4/10/24 - Form SC
- 3/27/24 - Form S-8
- 3/27/24 - Form 10-K
- ALT's page on the SEC website